Sec Form 3 Filing - HURLY STEPHEN A @ LAVA Therapeutics NV - 2025-01-01

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person HURLY STEPHEN A 2. Issuer Name and Ticker or Trading Symbol LAVA Therapeutics NV [ LVTX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) C/O LAVA THERAPEUTICS N.V., YALELAAN 62 3. Date of Earliest Transaction (MM/DD/YY) 01/01/2025 (Street) UTRECHT, P73584 CM 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Shares 5,000 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Share Options (Right to Buy) $ 2.35 ( 2 ) ( 1 ) 02/11/2030 Common Shares 232,934 D Share Options (Right to Buy) $ 2.35 ( 2 ) ( 3 ) 12/16/2030 Common Shares 134,368 D Share Options (Right to Buy) $ 2.35 ( 2 ) ( 4 ) 12/16/2030 Common Shares 360,451 D Share Options (Right to Buy) $ 5.1 ( 5 ) 12/20/2031 Common Shares 310,000 D Share Options (Right to Buy) $ 3.77 ( 6 ) 12/22/2032 Common Shares 800,000 D Share Options (Right to Buy) $ 1.59 ( 7 ) 01/18/2034 Common Shares 310,210 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other HURLY STEPHEN A C/O LAVA THERAPEUTICS N.V. YALELAAN 62 UTRECHT, P73584 CM X Chief Executive Officer Signatures /s/ Amy Garabedian, Attorney-in-Fact 01/02/2025 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Fully vested and immediately exercisable. ( 2 )Converted to U.S. dollars based on an exchange rate of 1.00 euro = $1.0389 (rounded to the nearest whole cent), the foreign exchange reference rate on December 31, 2024 as reported by the European Central Bank. Each option may be exercised for a price of 2.26 euros per share. ( 3 )33,592 of the shares underlying the option vested on December 16, 2021 and the remainder vests in 36 equal monthly installments beginning on January 16, 2022, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date. ( 4 )90,113 of the shares underlying the option vested on March 17, 2022 and the remainder vests in 36 equal monthly installments beginning on April 17, 2022, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date. ( 5 )The shares underlying the option vest in 48 equal monthly installments beginning on January 1, 2022, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date. ( 6 )The shares underlying the option vest in 48 equal monthly installments beginning on February 1, 2023, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date. ( 7 )The shares underlying the option vest in 48 equal monthly installments beginning on February 19, 2024, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.